Show simple item record

dc.contributor.authorSandmann, Lisa
dc.contributor.authorCornberg, Markus
dc.date.accessioned2021-06-08T08:49:26Z
dc.date.available2021-06-08T08:49:26Z
dc.date.issued2021-04-16
dc.identifier.citationJ Exp Pharmacol. 2020 Nov 16;12:503-515. doi: 10.2147/JEP.S273120.en_US
dc.identifier.issn1179-1454
dc.identifier.pmid33889032
dc.identifier.doi10.2147/JEP.S235550
dc.identifier.urihttp://hdl.handle.net/10033/622896
dc.description.abstractChronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.en_US
dc.language.isoenen_US
dc.publisherDovepressen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHBV/HDV coinfectionen_US
dc.subjectbulevirtideen_US
dc.subjecthepatitis deltaen_US
dc.subjectinterferonen_US
dc.subjectlonafarniben_US
dc.titleExperimental Drugs for the Treatment of Hepatitis D.en_US
dc.typeReviewen_US
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalJournal of experimental pharmacologyen_US
dc.source.volume13
dc.source.beginpage461
dc.source.endpage468
refterms.dateFOA2021-06-08T08:49:27Z
dc.source.journaltitleJournal of experimental pharmacology
dc.source.countryNew Zealand


Files in this item

Thumbnail
Name:
Sandmann and Cornberg.pdf
Size:
408.9Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International